Company news
BioXcel Therapeutics, Inc. news in 2019
BioXcel Therapeutics, Inc.'s news releases, calls and decks from 2019, newest first.
BioXcel Therapeutics Announces Initiation of Pivotal Phase 3 Studies of BXCL501 for Acute Treatment of Agitation in Patients with Schizophrenia and Bipolar Disorder
December 29, 2019
BioXcel Therapeutics to Expand Study of BXCL701 into Multiple Advanced Solid Tumor Types
December 10, 2019
BioXcel Therapeutics Prepares to Initiate Pivotal Phase 3 Studies with BXCL501 Following Positive End-of-Phase 2 Meeting with FDA
December 2, 2019
BioXcel Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update
November 13, 2019
BioXcel Therapeutics Announces BXCL501 Program Initiative for Prevention and Treatment of Acute Agitation using Wearable Digital Devices
September 17, 2019
Decks in 2019
- Investor Presentation (December 2019)
Investor deck · 26 slides · December 2019
- Corporate Update (July 2019)
Corporate update · 21 slides · Jul 22, 2019
- Investor Presentation (May 2019)
Investor deck · 17 slides · May 20, 2019
- Investor Presentation (March 2019)
Investor deck · 35 slides · Mar 12, 2019
- Corporate Update (January 2019)
Corporate update · 16 slides · Jan 3, 2019